Article Sidebar

PDF
Date Published: 28/06/2025
Abstract Views: 1
Views PDF: 2
DOI: https://doi.org/10.56535/jmpm.v50i5.1112
Issue
Vol. 50 No. 5 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 5 - 2025
Section
Articles
How to Cite
Trần, X. N., Nguyễn, A. T., Đỗ, T. K. T., Trương, Q. T., & Hoàng, B. H. (2025). SURVEY ON THE COMPLICATION RATE OF ENOXAPARIN INJECTION AND RELATED FACTORS IN PATIENTS AT THE INTENSIVE CARE UNIT. Journal of Military Pharmaco-medicine, 50(5), 141-150. https://doi.org/10.56535/jmpm.v50i5.1112

SURVEY ON THE COMPLICATION RATE OF ENOXAPARIN INJECTION AND RELATED FACTORS IN PATIENTS AT THE INTENSIVE CARE UNIT

Xuân Ngọc Trần1, Anh Tuấn Nguyễn1, Thị Kim Thu Đỗ2, Quang Trung Trương1,2, Bùi Hải Hoàng1,2,
1 Bệnh viện Đại học Y Hà Nội
2 Trường Đại học Y Hà Nội

Main Article Content

Abstract

Objective: The study was conducted to describe the rate of complications in patients using subcutaneous Enoxaparin and investigate factors associated with the risk of complications in the Emergency and Intensive Care Unit of Hanoi Medical University Hospital in 2024. Methods: A prospective observational study was performed on 55 intensive care patients receiving Enoxaparin. Results: The proportion of patients experiencing adverse effects from the drug was 90.9%. Of these, seven cases (14%) presented both systemic and local complications, while 43 cases (86%) had local complications. Conclusion: Factors associated with systemic complications included a history of bleeding, changes in glomerular filtration rate during treatment, a history of heart failure, and twice-daily dosing (p < 0.05). Factors related to complications at the injection site were age, weight, length of hospital stay, duration of drug use, history of hypertension, diabetes mellitus, and twice-daily dosing (p < 0.05).

Article Details

Keywords

Enoxaparin, anticoagulant, complications

References

1. Schulman S, Sholzberg M, Spyropoulos AC, et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost JTH. 2022; 20(10):2214-2225. DOI:10.1111/jth.15808.
2. Phạm Ngọc Đan, Nguyễn Minh Nhựt, Trương Ngọc Nguyên Khôi, Nguyễn Công Thành, Phạm Đăng Duy Quang. Tình trạng sử dụng thuốc kháng đông và biến cố xuất huyết trên bệnh nhân nhiễm SARS-CoV-2. J 108 - Clin Med Phamarcy. Published online October 16, 2023. DOI: 10.52389/ydls.v18idbv.1995
3. Journal of Cardiovascular Nursing. Accessed July 22, 2024. https://journals.lww.com/jcnjournal/abstract/2013/09000/occurrence_and_extent_of_bruising_according_to.11.aspx.
4. Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: A review. West J Emerg Med. 2015; 16(1):11-17. DOI:10.5811/westjem.2014.12.22933.
5. Nieuwenhuis H, Albada J, Banga J, Sixma J. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991; 78(9):2337-2343. DOI:10.1182/ blood.V78.9.2337.2337
6. Đinh Thị Lan Anh, Nguyễn Đức Trung, Phạm Văn Huy, Nguyễn Thị Thu Thủy, Nguyễn Thị Liên Hương. Phân tích đặc điểm sử dụng enoxaparin trên người bệnh điều trị nội trú tại Viện Tim mạch - Bệnh viện Trung ương Quân đội 108. J 108 - Clin Med Phamarcy. Published online April 1, 2021. DOI: 10.52389/ ydls.v16iDB4.1011
7. Zaki WE, Hassan MS, Mourad AH, Elnaby HAA. Effect of cold application on local problems among patients receiving subcutaneous enoxaparin. Egyptian Journal of Health Care. 2020; 11(1):219-233.
8. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020; 136(4):489-500. DOI:10.1182/ blood.2020006520.
9. Yi L juan, Shuai T, Tian X, Zeng Z, Ma L, Song G min. The effect of subcutaneous injection duration on patients receiving low-molecular-weight heparin: Evidence from a systematic review. Int J Nurs Sci. 2016; 3(1):79-88. DOI:10.1016/j.ijnss.2016.02.008.
10. Palese A, Aidone E, Dante P, Pea F. Occurrence and extent of bruising according to duration of administration of subcutaneous low-molecular-weight heparin: A quasi-experimental case-crossover study. J Cardiovasc Nurs. DOI:10.1097/JCN.0b013e3182578b87.